TOI Oncology Institute, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Oncology Institute, Inc. (TOI) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 12, 2026, a 10-Q quarterly report filed on November 13, 2025, an 8-K current report filed on March 13, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Oncology Institute, Inc. (TOI) (SEC CIK 1799191), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Reg FD disclosure filed as Exhibit 99.1 — contains material non-public information now being made public to all investors simultaneously
- • Exhibit furnished (not filed), limiting legal liability under Securities Exchange Act Section 18
Item 2.02: Results of Operations and Financial Condition
- • Q3 2023 earnings results disclosed via press release in Exhibit 99.1
- • Filing furnished (not filed) under SEC rules — limits legal liability but does not reduce informational significance to investors
Item 7.01: Regulation FD Disclosure
- • Reg FD disclosure filed, but substantive content resides in the referenced exhibit — no financial figures or operational data included in the item text itself
- • Boilerplate liability disclaimer confirms disclosed information is not incorporated by reference into future filings unless explicitly stated
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Kimberly Tzoumakas appointed to TOI Board via unanimous written consent, effective Feb 23, 2026, filling existing vacancy
- • Cleared Nasdaq independence requirements; no committee assignments yet
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Oncology Institute, Inc. (TOI) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 13, 2026 | — | Analysis | — |
10-K | Mar 12, 2026 | Dec 31, 2025 | — | |
8-K | Mar 12, 2026 | — | Analysis | — |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
8-K | Jan 7, 2026 | — | — | |
8-K | Dec 1, 2025 | — | — | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-K | Mar 26, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 13, 2024 | Jun 30, 2024 | — | |
10-Q | May 14, 2024 | Mar 31, 2024 | — | |
10-K | Mar 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 10, 2023 | Mar 31, 2023 | — | |
10-K | Mar 16, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Mar 11, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 16, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest TOI SEC filings in 2026?
Oncology Institute, Inc. (TOI) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on March 13, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TOI file its most recent 10-K annual report?
Oncology Institute, Inc. (TOI) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TOI 10-Q quarterly reports?
Oncology Institute, Inc. (TOI)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every TOI 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TOI filed recently?
Oncology Institute, Inc. (TOI)'s most recent 8-K was filed on March 13, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TOI insider trading activity (Form 4)?
SignalX aggregates every TOI Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TOI file with the SEC?
Oncology Institute, Inc. (TOI) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TOI filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Oncology Institute, Inc. (TOI).
What is TOI's SEC CIK number?
Oncology Institute, Inc. (TOI)'s SEC CIK (Central Index Key) number is 1799191. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1799191 to look up all TOI filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TOI return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Oncology Institute, Inc. (TOI) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Oncology Institute, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 30+ filings.